ArticleFrontiers in oncology2020

Combination of T-Cell Bispecific Antibodies With PD-L1 Checkpoint Inhibition Elicits Superior Anti-Tumor Activity.

Johannes Sam et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.